Acorda Therapeutics, Inc. (NASDAQ:ACOR) Files An 8-K Other Events
Item 8.01Other Events
On March 9, 2017, Acorda Therapeutics, Inc. announced that the
United States Patent and Trademark Office (USPTO) Patent Trials
and Appeal Board (PTAB) upheld all four patents challenged via
the inter partes review (IPR) process. U.S. Patent Nos. 8,663,685
(the 685 patent), 8,440,703 (the 703 patent), 8,354,437 (the 437
patent) and 8,007,826 (the 826 patent) apply to AMPYRA
(dalfampridine) Extended Release Tablets, 10 mg. These patents
are set to expire in 2025, 2025, 2026 and 2027, respectively.
These patents, as well as U.S. Patent No. 5,540,938 that also
pertains to AMPYRA, have also been challenged in the U.S.
District Court for the District of Delaware. The Court has
completed the trial of the case, but not yet issued its decision.
A copy of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated by reference into
this Item.
Item 9.01Financial Statements and Exhibits
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated March 9, 2017 |
About Acorda Therapeutics, Inc. (NASDAQ:ACOR)
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. Its research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. Its Ampyra is an oral drug for the treatment to improve walking in patients with multiple sclerosis. Zanaflex Capsules and tablets are used as short-acting drugs for the management of spasticity. Qutenza is a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Its pipeline of neurological therapies addresses a range of disorders, including Parkinson’s disease, chronic post-stroke walking deficits and migraine. Acorda Therapeutics, Inc. (NASDAQ:ACOR) Recent Trading Information
Acorda Therapeutics, Inc. (NASDAQ:ACOR) closed its last trading session up +1.85 at 30.15 with 982,213 shares trading hands.
